Vestnik dermatologii i venerologiiVestnik dermatologii i venerologii0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov96110.25208/vdv961Personalized approach to the selection of therapy for patients with psoriasisbased on the results of molecular and genetic testsZnamenskayaL Fznaml@cnikvi.ruFrigoN V-RotanovS V-VolkovI A-VolnukhinV A-ZhilovaM B-15102010865778311032020Copyright © 2010, Znamenskaya L.F., Frigo N.V., Rotanov S.V., Volkov I.A., Volnukhin V.A., Zhilova M.B.2010The article presents the results of tests aimed at revealing biomarkers of patients clinical response to treatment with Infliximab
and phototherapy with the use of molecular and genetic technologies. The authors revealed that the predictor of evident clinical
response to treatment of psoriasis patients with Infliximab is the homozygous TT genotype at the 676 locus of exon 6 of the TNFR-
II gene; predictors of high efficacy and safety of treatment of psoriasis patients with Infliximab with the use of ultraviolet therapy
(PUVA and mid-wavelength ultraviolet therapy (311 nm)) are: heterozygous GA genotype at the 19007 locus of the ERCC gene
and homozygous CC genotype at the 27945 locus of the XPF gene.psoriasisInfliximabphototherapyproteome analysispersonalization of treatmentgenotypes at the 676 locus of exon 6 of the TNF-R-II geneGA at the 19007 locus of the ERCC gene and CC at the 27945 locus of the XPF geneпсориазинфликсимабфототерапияпротеомный анализперсонализация лечениягенотипы в позиции 676 шестого экзона гена TNF-RIIGA в позиции 19007 гена ERCC и СС в позиции 27945 гена XPF[Jariwala S.P. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007 Oct; 299(8): 359-66.][Mahlknecht U., Voelter-Mahlknecht S. Pharmacogenomics: questions and concerns. Curr Med Res Opin 2005; 21(7): 1041-1047.][Global Technology Center, Health Research Institute. Personalized Medicine. The Emerging Pharmacogenomics Revolution. Pricewaterhouse Coopers, February, 2005.][Sadee W. Pharmacogenomics. BMJ 1999; 319: 1286.][Mascheretti S., Hampe J., Kuhbacher T. et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2 (2): 127-136.][Matsukura H., Ikeda S., Yoshimura N. et al. Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRSF1B) affect responses to infliximab in Crohn's disease patients in Japan. Aloment Pharmacol Ther 2008, Jan 28.]